Nanomaterial-based ophthalmic therapies

References

• 1. Gote V, Sikder S, Sicotte J, Pal D. Ocular drug delivery: present innovations and future challenges. J. Pharmacol. Exp. Ther. 370(3), 602–624 (2019).
  Medline CASGoogle Scholar
• 2. Sampat KM, Garg SJ. Complications of intravitreal injections. Curr. Opin. Ophthalmol. 21(3), 178–183 (2010).
  MedlineGoogle Scholar
• 3. Wong WL, Su X, Li X et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob. Health 2(2), e106–e116 (2014).
  MedlineGoogle Scholar
• 4. Ferris FL 3rd, Wilkinson CP, Bird A et al. Clinical classification of age-related macular degeneration. Ophthalmology 120(4), 844–851 (2013).
  MedlineGoogle Scholar
• 5. Flores R, Carneiro A, Vieira M, Tenreiro S, Seabra MC. Age-related macular degeneration: pathophysiology, management, and future perspectives. Ophthalmologica 244(6), 495–511 (2021).
  Medline CASGoogle Scholar
• 6. Lin TC, Hung KH, Peng CH et al. Nanotechnology-based drug delivery treatments and specific targeting therapy for age-related macular degeneration. J. Chin. Med. Assoc. 78(11), 635–641 (2015).
  MedlineGoogle Scholar
• 7. Bourne RRA, Jonas JB, Bron AM et al. Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe in 2015: magnitude, temporal trends and projections. Brit. J. Ophthalmol. 102(5), 575–585 (2018).
  MedlineGoogle Scholar
• 8. Boehm BO, Lang G, Feldmann B et al. Proliferative diabetic retinopathy is associated with a low level of the natural ocular anti-angiogenic agent pigment epithelium-derived factor (PEDF) in aqueous humor. A pilot study. Horm. Metab. Res. 35(6), 382–386 (2003).
  Medline CASGoogle Scholar
• 9. Visvesvara GS, Moura H, Schuster FL. Pathogenic and opportunistic free-living amoebae: Acanthamoeba spp., Balamuthia mandrillaris, Naegleria fowleri, and Sappinia diploidea. Fems. Immunol. Med. Mic. 50(1), 1–26 (2007).
  Medline CASGoogle Scholar
• 10. Lorenzo-Morales J, Khan NA, Walochnik J. An update on Acanthamoeba keratitis: diagnosis, pathogenesis and treatment. Parasite 22, 10 (2015).
  MedlineGoogle Scholar
• 11. CDC. Parasites–Acanthamoeba–granulomatous amebic encephalitis (gae); keratitis (2013). www.cdc.gov/parasites/acanthamoeba/health_professionals/index.html (Accessed 24 March 2023).
  Google Scholar
• 12. Carnt N, Stapleton F. Strategies for the prevention of contact lens-related Acanthamoeba keratitis: a review. Ophthal. Phys. Opt. 36(2), 77–92 (2016).
  MedlineGoogle Scholar
• 13. Martin-Navarro CM, Lorenzo-Morales J, Machin RP et al. Inhibition of 3-hydroxy-3-methylglutaryl-coenzyme a reductase and application of statins as a novel effective therapeutic approach against Acanthamoeba infections. Antimicrob. Agents Chemother. 57(1), 375–381 (2013).
  Medline CASGoogle Scholar
• 14. Tham Y-C, Li X, Wong TY, Quigley HA, Aung T, Cheng C-Y. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology 121(11), 2081–2090 (2014).
  MedlineGoogle Scholar
• 15. Peng JJ, Song WT, Yao F et al. Involvement of regulated necrosis in blinding diseases: focus on necroptosis and ferroptosis. Exp. Eye Res. 191, 107922 (2020).
  Medline CASGoogle Scholar
• 16. Pasparakis M, Vandenabeele P. Necroptosis and its role in inflammation. Nature 517(7534), 311–320 (2015).
  Medline CASGoogle Scholar
• 17. Mifflin L, Ofengeim D, Yuan J. Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target. Nat. Rev. Drug Discov. 19(8), 553–571 (2020).
  Medline CASGoogle Scholar
• 18. Das S, Singh S, Kumar A. Bacterial burden declines but neutrophil infiltration and ocular tissue damage persist in experimental Staphylococcus epidermidis endophthalmitis. Front. Cell Infect. Microbiol. 11, 780648 (2021).
  Medline CASGoogle Scholar
• 19. Sahay P, Goel S, Nagpal R et al. Infectious keratitis caused by rare and emerging micro-organisms. Curr. Eye Res. 45(7), 761–773 (2020).
  Medline CASGoogle Scholar
• 20. Thomas RK, Melton R, Asbell PA. Antibiotic resistance among ocular pathogens: current trends from the ARMOR surveillance study (2009–2016). Clin. Optom. 11, 15–26 (2019).
  MedlineGoogle Scholar